Is Energy Transfer a Good Dividend Stock to Buy Now?
Energy Transfer (NYSE:ET) offers an impressive yield, to say the…
Sell
41
AZN Quote, Financials, Valuation and Earnings
Last price:
$67.82
Seasonality move
:
4.94%
Day range:
$64.45 - $66.62
52-week range:
$61.24 - $87.68
Dividend yield:
2.34%
P/E ratio:
29.40x
P/S ratio:
3.83x
P/B ratio:
5.05x
Volume:
5.7M
Avg. volume:
6.5M
1-year change:
-4.55%
Market cap:
$205.5B
Revenue:
$54.1B
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.7B | $1.11 | 8.46% | 83.1% | $85.68 |
|
AMGN
Amgen
|
$8.1B | $4.29 | 5.62% | 286.04% | $316.99 |
|
GSK
GSK PLC
|
$9.6B | $0.98 | 2.49% | 46.01% | $43.55 |
|
JNJ
Johnson & Johnson
|
$21.6B | $2.58 | 0.55% | 38.85% | $169.87 |
|
MRNA
Moderna
|
$130.3M | -$3.10 | -19.37% | -0.05% | $52.05 |
|
SNY
Sanofi SA
|
$11.1B | $0.95 | -15.85% | 82.5% | $63.84 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$66.29 | $85.68 | $205.5B | 29.40x | $1.05 | 2.34% | 3.83x |
|
AMGN
Amgen
|
$285.98 | $316.99 | $153.6B | 37.88x | $2.38 | 3.19% | 4.62x |
|
GSK
GSK PLC
|
$34.64 | $43.55 | $70.6B | 21.88x | $0.40 | 4.49% | 1.79x |
|
JNJ
Johnson & Johnson
|
$151.73 | $169.87 | $365.6B | 26.21x | $1.24 | 3.27% | 4.15x |
|
MRNA
Moderna
|
$26.20 | $52.05 | $10.1B | -- | $0.00 | 0% | 3.18x |
|
SNY
Sanofi SA
|
$51.50 | $63.84 | $129.1B | 20.61x | $2.04 | 7.65% | 2.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.27% | -0.160 | -- | 0.74x |
|
AMGN
Amgen
|
91.09% | 0.284 | 43.85% | 0.84x |
|
GSK
GSK PLC
|
53.74% | -0.068 | 29.19% | 0.49x |
|
JNJ
Johnson & Johnson
|
33.88% | 0.428 | 10.52% | 0.86x |
|
MRNA
Moderna
|
-- | 0.004 | -- | 3.45x |
|
SNY
Sanofi SA
|
17.11% | 0.103 | 13.73% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
JNJ
Johnson & Johnson
|
$15.4B | $3.8B | 13.3% | 19.98% | 17.87% | $4.8B |
|
MRNA
Moderna
|
$217M | -$1.2B | -29.09% | -29.09% | -123.22% | $303M |
|
SNY
Sanofi SA
|
$5.7B | $917.8M | 6.07% | 7.55% | 4.64% | -$498.5M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 6.9%. AstraZeneca PLC's return on equity of 17.77% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 29.26%. On the other hand Amgen has an analysts' consensus of $316.99 which suggests that it could grow by 11%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 AMGNAmgen9 14 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.34%. Amgen offers a yield of 3.19% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Amgen quarterly revenues of $9.1B. AstraZeneca PLC's net income of $1.5B is higher than Amgen's net income of $627M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.40x while Amgen's PE ratio is 37.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.83x versus 4.62x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.83x 29.40x $14.9B $1.5B AMGNAmgen4.62x 37.88x $9.1B $627M
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 5.1%. AstraZeneca PLC's return on equity of 17.77% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 29.26%. On the other hand GSK PLC has an analysts' consensus of $43.55 which suggests that it could grow by 25.71%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 GSKGSK PLC2 3 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.135%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.34%. GSK PLC offers a yield of 4.49% to investors and pays a quarterly dividend of $0.40 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.5B is higher than GSK PLC's net income of $530.1M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.40x while GSK PLC's PE ratio is 21.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.83x versus 1.79x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.83x 29.40x $14.9B $1.5B GSKGSK PLC1.79x 21.88x $10.4B $530.1M
-
Which has Higher Returns AZN or JNJ?
Johnson & Johnson has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 15.24%. AstraZeneca PLC's return on equity of 17.77% beat Johnson & Johnson's return on equity of 19.98%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B JNJJohnson & Johnson68.35% $1.41 $108.1B -
What do Analysts Say About AZN or JNJ?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 29.26%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that AstraZeneca PLC has higher upside potential than Johnson & Johnson, analysts believe AstraZeneca PLC is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 JNJJohnson & Johnson7 11 0 -
Is AZN or JNJ More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.
-
Which is a Better Dividend Stock AZN or JNJ?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.34%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or JNJ?
AstraZeneca PLC quarterly revenues are $14.9B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AstraZeneca PLC's net income of $1.5B is lower than Johnson & Johnson's net income of $3.4B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.40x while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.83x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.83x 29.40x $14.9B $1.5B JNJJohnson & Johnson4.15x 26.21x $22.5B $3.4B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 10.07% compared to AstraZeneca PLC's net margin of -117.16%. AstraZeneca PLC's return on equity of 17.77% beat Moderna's return on equity of -29.09%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B MRNAModerna22.7% -$2.91 $10.9B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 29.26%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 98.66%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 MRNAModerna5 17 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.34%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Moderna quarterly revenues of $956M. AstraZeneca PLC's net income of $1.5B is higher than Moderna's net income of -$1.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.40x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.83x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.83x 29.40x $14.9B $1.5B MRNAModerna3.18x -- $956M -$1.1B
-
Which has Higher Returns AZN or SNY?
Sanofi SA has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 6.54%. AstraZeneca PLC's return on equity of 17.77% beat Sanofi SA's return on equity of 7.55%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B SNYSanofi SA70.24% $0.29 $97.7B -
What do Analysts Say About AZN or SNY?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 29.26%. On the other hand Sanofi SA has an analysts' consensus of $63.84 which suggests that it could grow by 23.96%. Given that AstraZeneca PLC has higher upside potential than Sanofi SA, analysts believe AstraZeneca PLC is more attractive than Sanofi SA.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 SNYSanofi SA5 2 0 -
Is AZN or SNY More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.246%.
-
Which is a Better Dividend Stock AZN or SNY?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.34%. Sanofi SA offers a yield of 7.65% to investors and pays a quarterly dividend of $2.04 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SNY?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Sanofi SA quarterly revenues of $8.1B. AstraZeneca PLC's net income of $1.5B is higher than Sanofi SA's net income of $531.9M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.40x while Sanofi SA's PE ratio is 20.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.83x versus 2.68x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.83x 29.40x $14.9B $1.5B SNYSanofi SA2.68x 20.61x $8.1B $531.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Did the Market Bottom Already?
The past few weeks have been among the most volatile…
Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 14
Regencell Bioscience Holdings [RGC] is down 9.04% over the past day.
Buy
52
SLP alert for Apr 14
Simulations Plus [SLP] is up 1.87% over the past day.
Sell
38
ZLAB alert for Apr 14
Zai Lab [ZLAB] is up 6.26% over the past day.
